Combined Positive Score and Cisplatin Sensitivity Are Prognostic Factors for Response to Nivolumab Therapy for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck

Combined Positive Score and Cisplatin Sensitivity Are Prognostic Factors for Response to Nivolumab Therapy for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck

Background: Recurrent or metastatic squamous cell carcinoma of the head and neck (R/MHNSCC) is a challenging malignancy with a poor prognosis and limited treatment options. Nivolumab, an immune checkpoint inhibitor (ICI) targeting the programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1)...

Full description

Saved in:
Bibliographic Details
Main Authors: Hiroaki Iijima, Akihiro Sakai, Koji Ebisumoto, Go Ogura, Mayu Yamauchi, Takanobu Teramura, Aritomo Yamazaki, Takane Watanabe, Toshihide Inagi, Ryoko Yanagiya, Ai Yamamoto, Hiroshi Ashida, Yoshiyuki Ota, Yurina Sato, Naoya Kobayashi, Daisuke Maki, Naoya Nakamura, Kenji Okami
Format: Article
Language:English
Published: SAGE Publishing 2024-10-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.1177/11795549241290030
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/11795549241290030

Similar Items